Dr. Garraway summarizes SUO session on early detection and treatment of prostate cancer
“It’s really important to look at the pathology we’ve learned before considering these patients for active surveillance treatment,” says Isla Garraway, MD, PhD.
In this video, Isla Garraway, MD, PhD, discusses key points of the session on early detection and treatment of prostate cancer that was presented at the 2021 Society of Urologic Oncology Annual Meeting. Garraway is an associate professor and director of research in the department of urology, and a member of the Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine at the UCLA School of Medicine in Los Angeles, California.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
